Form 8-K - Current report:
SEC Accession No. 0001193125-24-231158
Filing Date
2024-10-02
Accepted
2024-10-02 16:10:54
Documents
14
Period of Report
2024-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d875044d8k.htm   iXBRL 8-K 27745
2 EX-10.2 d875044dex102.htm EX-10.2 35395
  Complete submission text file 0001193125-24-231158.txt   196054

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aldx-20240930.xsd EX-101.SCH 2841
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20240930_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20240930_pre.xml EX-101.PRE 11255
16 EXTRACTED XBRL INSTANCE DOCUMENT d875044d8k_htm.xml XML 3642
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 241347403
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)